title: [The efficacy of transarterial immuno-embolization therapy in patients with unresectable hepatocellular carcinoma].
abstract: We devised a new therapeutic modality for multiple hepatocellular carcinoma (HCC) consisting of transarterial immuno-embolization (TIE) using OK-432 and fibrinogen, and applied the treatment to 22 patients with advanced HCC who had been insensitive to TAE, and 21 patients who had no treatment. Nineteen patients had a high AFP level of more than 200 ng/ml. The serum AFP level decreased in 15 patients after TIE, and in 7 patients the AFP level decreased to less than 30%. Furthermore, a marked reduction in tumor size was observed in 69% after TIE. We report 61% 1-year, and 3-year survival rate for cases who had been insensitive to TAE, and 86% 2-year survival rate for those who selected TIE as the first choice. A high fever of more than 38 degrees C occurred in all cases, and hypotension less than 80 mmHg was observed in 42% patients. No deterioration of liver function and no disturbance of the coagulation-fibrinolysis system due to TIE except in one patient with liver failure after TIE.
authors.affiliation: Dept. of Surgery II, Osaka University Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: T
authors.initials: T
authors.lastname: Kanai
authors.forename: M
authors.initials: M
authors.lastname: Sakon
authors.forename: Y
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: N
authors.initials: N
authors.lastname: Higaki
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Taniguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuike
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D004621:Embolization, Therapeutic; D005340:Fibrinogen / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000008:administration & dosage*
chemical_list: D010844:Picibanil; D005340:Fibrinogen